Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2014 1
2017 1
2018 2
2020 1
2021 1
2023 1
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

6 results

Results by year

Filters applied: . Clear all
Page 1
Noninvasive biomarkers in NAFLD and NASH - current progress and future promise.
Wong VW, Adams LA, de Lédinghen V, Wong GL, Sookoian S. Wong VW, et al. Nat Rev Gastroenterol Hepatol. 2018 Aug;15(8):461-478. doi: 10.1038/s41575-018-0014-9. Nat Rev Gastroenterol Hepatol. 2018. PMID: 29844588 Review.
Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is the most common chronic liver disease worldwide. ...With an increasing number of patients developing NASH-related end-stage liver …
Nonalcoholic fatty liver disease (NAFLD) affects 25% of the global adult population and is the most common chron …
Role of extracellular vesicles in nonalcoholic fatty liver disease.
Jiang W, Xu Y, Chen JC, Lee YH, Hu Y, Liu CH, Chen E, Tang H, Zhang H, Wu D. Jiang W, et al. Front Endocrinol (Lausanne). 2023 Jul 18;14:1196831. doi: 10.3389/fendo.2023.1196831. eCollection 2023. Front Endocrinol (Lausanne). 2023. PMID: 37534206 Free PMC article. Review.
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease that affects approximately one-quarter of the global population and is becoming increasingly prevalent worldwide. ...Herein, we summarize the roles of …
BACKGROUND: Nonalcoholic fatty liver disease (NAFLD) is a common chronic liver disease that affect …
Liver fat quantification: where do we stand?
Starekova J, Reeder SB. Starekova J, et al. Abdom Radiol (NY). 2020 Nov;45(11):3386-3399. doi: 10.1007/s00261-020-02783-1. Epub 2020 Oct 6. Abdom Radiol (NY). 2020. PMID: 33025153 Free PMC article. Review.
In the absence of secondary cause, the term nonalcoholic fatty liver disease (NAFLD) is used. Hepatic steatosis may progress into nonalcoholic steatohepatitis, the more aggressive form of NAFLD, associated with hepatic complications such …
In the absence of secondary cause, the term nonalcoholic fatty liver disease (NAFLD) is used. Hepatic steatosis …
MicroRNAs as biomarkers for clinical studies.
Pogribny IP. Pogribny IP. Exp Biol Med (Maywood). 2018 Feb;243(3):283-290. doi: 10.1177/1535370217731291. Epub 2017 Sep 15. Exp Biol Med (Maywood). 2018. PMID: 28914096 Free PMC article. Review.
Commonly reported microRNAs as disease biomarkers are largely not disease-specific and the results are often contradicting in independent studies. This review summarizes the current knowledge on the role of microRNAs as disease indicators and em …
Commonly reported microRNAs as disease biomarkers are largely not disease-specific and the results are often contradict …
Current status of fibrosis markers.
Patel K, Shackel NA. Patel K, et al. Curr Opin Gastroenterol. 2014 May;30(3):253-9. doi: 10.1097/MOG.0000000000000059. Curr Opin Gastroenterol. 2014. PMID: 24671009 Review.
RECENT FINDINGS: Many noninvasive approaches initially developed for binary disease staging in CHC continue to be refined for diagnostic use in other chronic liver disease such as NAFLD. ...Reliable biomarkers for steatosis, nonalcoholic …
RECENT FINDINGS: Many noninvasive approaches initially developed for binary disease staging in CHC continue to be refined for …
Nonalcoholic Fatty Liver Disease (NAFLD) as Model of Gut-Liver Axis Interaction: From Pathophysiology to Potential Target of Treatment for Personalized Therapy.
Fianchi F, Liguori A, Gasbarrini A, Grieco A, Miele L. Fianchi F, et al. Int J Mol Sci. 2021 Jun 17;22(12):6485. doi: 10.3390/ijms22126485. Int J Mol Sci. 2021. PMID: 34204274 Free PMC article. Review.
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide, affecting both adults and children and will result, in the near future, as the leading cause of end-stage liver disease. ...As …
Nonalcoholic fatty liver disease (NAFLD) is the leading cause of liver disease worldwide, affectin …